Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYFTREK ...

A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.

Discover reviews, ratings, and trailers for Devil's Triangle (2021) on Rotten Tomatoes. Stay updated with critic and audience scores today!

Vertex Pharma says its much-anticipated non-opioid painkiller, VX-548, clears two phase 3 trials en route to an FDA filing later this year.

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...

Penserra Capital Management significantly reduced its stake in Vertex Pharmaceuticals, dropping 81% of its shares in the ...

Read about Vertex Pharmaceuticals Inc (VRTX:XNAS) stock and today's latest news and financial updates.

View the most recent data and latest information on option chains for Vertex Pharmaceuticals Incorporated Common Stock (VRTX) at Nasdaq.com.